Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment
Chemical and Pharmaceutical Bulletin · 2025
DOI: 10.1248/cpb.c24-00796 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical and Pharmaceutical Bulletin, 2025. Verfasst von Keita Kajino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Science and Technology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8571, Japan. Hauptthemen laut MEDLINE: Receptors, Opioid, delta, Quinolines, GTP-Binding Proteins, beta-Arrestins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Abstract (Originalsprache)
The δ-opioid receptor (DOR) continues to attract attention as a therapeutic target for the development of safer analgesics due to its ability to mediate pain relief with a lower risk of adverse effects compared to the μ-opioid receptor (MOR). Building upon our previous findings on KNT-127, a DOR-selective agonist with a morphinan scaffold, this study further explores the structure-signal relationships between quinoline ring modifications and the signaling bias toward Gi-protein activation while minimizing β-arrestin-2 recruitment. Our findings highlight the critical role of the 5'-position in modulating signaling bias. Bulky hydrophobic substituents, such as isopropoxy and cyclohexanoxy groups, effectively reduce β-arrestin-2 recruitment without compromising DOR binding affinity or Gi-protein activation. Molecular-docking and molecular dynamics simulations provided mechanistic insights, showing that these modifications change ligand interactions with the V2816.55-W2846.58-L3007.35 sub-pocket, thus selectively favoring Gi-protein signaling. These insights clarify the key interactions for the signaling bias in DOR agonists, offering a new framework for the design of DOR-targeted therapies with an improved therapeutic profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Science and Technology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8571, Japan.
- International Institute for Integrative Sleep Medicine (WPI-IIIS), University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
- Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3 Aoba, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
- Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
- Division of Biomedical Science, Institute of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-575, Japan.
- Transborder Medical Research Center, University of Tsukuba, 11-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Zitieren
APA
Kajino, K., Sugai, T., Kakumoto, T., Kise, R., Suzuki, R., Tokuda, A., Sekiya, Y., Katamoto, R., Kutsumura, N., Nagumo, Y., Hirokawa, T., Inoue, A., & Saitoh, T. (2025). Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment. Chemical and Pharmaceutical Bulletin. https://doi.org/10.1248/cpb.c24-00796
Vancouver
Kajino K, Sugai T, Kakumoto T, Kise R, Suzuki R, Tokuda A, et al. Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment. Chemical and Pharmaceutical Bulletin. 2025. doi:10.1248/cpb.c24-00796
BibTeX
@article{Kajino2025,
author = {Kajino, Keita and Sugai, Tomoya and Kakumoto, Tomoya and Kise, Ryoji and Suzuki, Riko and Tokuda, Akihisa and Sekiya, Yuki and Katamoto, Risako and Kutsumura, Noriki and Nagumo, Yasuyuki and Hirokawa, Takatsugu and Inoue, Asuka and Saitoh, Tsuyoshi},
title = {Structure–Signal Relationships of the δ-Opioid-Receptor (DOR)-Selective Agonist KNT-127—Part II: Quinoline Ring Modifications for Enhanced G-Protein Signaling and Reduced β-Arrestin Recruitment},
journal = {Chemical and Pharmaceutical Bulletin},
year = {2025},
doi = {10.1248/cpb.c24-00796}
}
EUVIMED